Author： Mellgren ÅÅsa
Publisher： Future Medicine
ISSN： 1479-6708
Source： Future Neurology, Vol.3, Iss.5, 2008-09, pp. : 565-574
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
HIV-1 is a virus with neurotropic features causing major morbidity and also mortality if untreated. Mild symptoms of neurocognitive impairment are common and precede more severe forms of dementia, termed AIDS dementia complex (ADC). The pathogenesis of neurodegeneration in HIV-1 infection is not fully understood, and we lack specific markers to verify the diagnosis. Fortunately, antiretroviral treatment is effective in treating both systemic and CNS infection, and neurocognitive symptoms and ADC will, in most cases, improve on treatment. This review focuses on current research regarding cerebral spinal fluid biomarkers and effects of highly active antiretroviral treatment on HIV-1 CNS disease.
Related content
Access to resources
Recommend
Brain, Vol. 125, Iss. 12, 2002-12 ,pp. :
Quality of Life with Brain Damage
Brain and Language, Vol. 71, Iss. 1, 2000-01 ,pp. :